New therapy to reduce severe COVID-19 damage using renalase
New target and new therapy for severe Covid-19 and viral hyperinflammation damage: renalase and renalase agonists
This study is testing a new treatment called BP-1002 to help reduce inflammation and protect the organs of people with severe COVID-19, with the hope that it can improve their recovery and overall health.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bessor Pharma, LLC NIH-funded |
| Lab location | 1 site (Framingham, United States) |
| Project ID | NIH-10924059 on NIH RePORTER |
What this research studies
This research focuses on developing a new therapeutic agent called BP-1002, which aims to reduce inflammation and protect tissues in patients suffering from severe COVID-19. BP-1002 acts as a renalase agonist, promoting cell survival and downregulating inflammatory responses through specific signaling pathways. The approach involves synthesizing a stable and easily manufactured version of renalase that can be administered to patients. Preliminary data suggest that this therapy could significantly improve outcomes for those affected by COVID-19 and its complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing severe COVID-19 symptoms or complications related to the virus.
Not a fit: Patients with mild COVID-19 symptoms or those who have fully recovered from the virus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that prevents organ injury and reduces mortality in severe COVID-19 cases.
How similar studies have performed: Other research has shown promising results with similar approaches targeting inflammatory responses in viral infections, indicating potential for success.
Where this research is happening
Framingham, United States
- Bessor Pharma, LLC — Framingham, United States (Active)
Researchers
- Principal investigator: Berkowitz, Barry a — Bessor Pharma, LLC
- Study coordinator: Berkowitz, Barry a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.